Phoenix Financial Ltd. Acquires 992 Shares of Thermo Fisher Scientific Inc. $TMO

Phoenix Financial Ltd. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,887 shares of the medical research company’s stock after buying an additional 992 shares during the period. Phoenix Financial Ltd.’s holdings in Thermo Fisher Scientific were worth $2,000,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in TMO. CBIZ Investment Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. DiNuzzo Private Wealth Inc. increased its stake in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the period. Finally, HighMark Wealth Management LLC increased its stake in Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after purchasing an additional 45 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.9%

TMO stock opened at $559.48 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $211.27 billion, a price-to-earnings ratio of 32.36, a price-to-earnings-growth ratio of 3.14 and a beta of 0.77. The business’s 50 day moving average price is $499.00 and its two-hundred day moving average price is $450.49.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the company posted $5.37 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. UBS Group lifted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Barclays upped their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Evercore ISI upped their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, William Blair initiated coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating on the stock. Fifteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $581.72.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.